Physician profile
David D Gill
NPI 1447562236
$5,052.06
in general payments reported to CMS, 2019-2025
47 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $339 · 2021: $883 · 2022: $605 · 2023: $1,155 · 2024: $1,182 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.96 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.43 | 2020-2025 | |
| Biogen, INC. | $328.46 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $230.67 | 2020-2025 | Briviact, Nayzilam |
| Pfizer INC. | $192.66 | 2023-2025 | |
| Lilly USA, LLC | $176.67 | 2019-2024 | Amyvid, Reyvow, Emgality |
| Celgene Corporation | $173.77 | 2021-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $172.28 | 2019-2024 | |
| Acorda Therapeutics, INC | $168.28 | 2019-2024 | Inbrija |
| Neurocrine Biosciences, INC. | $154.71 | 2020-2024 | Ingrezza, Ongentys |
| Lundbeck LLC | $150.55 | 2020-2024 | Rexulti, Vyepti |
| Biohaven Pharmaceuticals, INC. | $130.35 | 2021 | |
| Amgen INC. | $108.12 | 2020-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $105.74 | 2020-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $104.17 | 2023-2024 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $100.52 | 2021-2024 | Ultomiris |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.